Clinical trial · no report yet · Phase not applicable
ARREST 2
Ablative Radiotherapy to Restrain Every Metastasis Safely Treatable (ARREST-2): A Randomized Phase II/III Trial
- NCT05508464 ↗
- Recruiting
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 11 | |
| YouTube | 1 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- Ablative Radiotherapy to Restrain Every Metastasis Safely Treatable (ARREST-2): A Randomized Phase II/III Trial
- Phase
- Phase not applicable
- Status
- Recruiting
- Conditions
- Metastatic Cancer
- Interventions
- Arm 2: SABR; Arm 1: Standard of Care
- Arms
- Standard of Care · Active comparator
- SABR · Active comparator
- Enrollment
- 138 (estimated)
- Primary outcomes
- Overall Survival
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Start
- Oct 16, 2023
- Primary completion
- Jan 1, 2034 (estimated)
- Results posted
- No
- Registry record
- NCT05508464 · updated Jun 29, 2026